Role of metformin, Sodium-Glucose Cotransporter-2 (SGLT2) Inhibitors, Glucagon-Like Peptide-1 (GLP-1) receptor agonists, and orlistat based multidrug therapy in glycemic control, weight loss, and euglycemia in diabesity: A real-world experience-Reference-Cited by-同舟云学术

Role of metformin, Sodium-Glucose Cotransporter-2 (SGLT2) Inhibitors, Glucagon-Like Peptide-1 (GLP-1) receptor agonists, and orlistat based multidrug therapy in glycemic control, weight loss, and euglycemia in diabesity: A real-world experience

Published:2019 Issue:4 Volume:23 Page:460
ISSN:2230-8210
Container-title:Indian Journal of Endocrinology and Metabolism
language:en
Short-container-title:Indian J Endocr Metab

Author:

Dutta Deep,Jaisani Ritu,Khandelwal Deepak,Ghosh Soumitra,Malhotra Rajiv,Kalra Sanjay

Publisher

Medknow

Subject

Endocrinology,Endocrinology, Diabetes and Metabolism

Cited by 12 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Efficacy and Safety of Cagrilintide Alone and in Combination with Semaglutide (Cagrisema) as Anti-Obesity Medications: A Systematic Review and Meta-Analysis;Indian Journal of Endocrinology and Metabolism;2024-09-04

2. Orforglipron, a novel non‐peptide oral daily glucagon‐like peptide‐1 receptor agonist as an anti‐obesity medicine: A systematic review and meta‐analysis;Obesity Science & Practice;2024-02-26

3. Observation on clinical effect of Huoxue-Jiangtang decoction formula granules in treating prediabetes: a randomized prospective placebo-controlled double-blind trial protocol;BMC Complementary Medicine and Therapies;2022-10-19

4. ESI Clinical Practice Guidelines for the Evaluation and Management of Obesity In India;Indian Journal of Endocrinology and Metabolism;2022-07

5. Reversal and Remission of T2DM – An Update for Practitioners;Vascular Health and Risk Management;2022-06